| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Treatment and prevention of thrombotic diseases such as cerebral infarction and myocardial infarction are extremely important. As a result of searching thrombolysis-enhancing substances using in vitro thrombolytic activity evaluation system, we have discovered cyclic pentapeptide malformin. The purpose of this study is to elucidate the mechanism of action for malformin. In this study, we showed that malformin induces the activation of RSK1, raises the expression of urokinase and promotes fibrinolytic activity via plasminogen activation in plasma fluid. From the results of this study, it is expected to create the next generation thrombolytic agent based on the molecular structure of malformin.
|
